# Etelcalcetide (Parsabiv)

> Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.

Source: https://peptides.cafe/peptide/etelcalcetide
Category: Calcium-Sensing Receptor Agonist · Endocrine
Tag: FDA-Approved · Endocrine

## Mechanism
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.

## Research areas
- Secondary hyperparathyroidism in adults on chronic hemodialysis

## Common research protocols
- IV three times weekly: 5 mg IV bolus at end of hemodialysis three times weekly; titrate.

## Study summaries
- "Etelcalcetide vs cinacalcet" — JAMA (2017): Non-inferior PTH reduction with IV administration.

## Considerations
- FDA-approved.
- Hypocalcemia common; monitor calcium and avoid in low corrected calcium.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.